Objective:To correlate homocysteine (Hcy) and blood lipid levels with neurological function in patients with progressive ischemic stroke.Methods:A total of 400 patients with ischemic stroke who received treatment between June 2018 and June 2020 in Linhai Second People's Hospital were included in this study. Progressive ischemic stroke ( n = 126) and non-progressive ischemic stroke ( n = 274) groups were designated. Hcy level was determined by enzyme-linked immunosorbent assay. High-density lipoprotein cholesterol, triacylglycerol, low-density lipoprotein cholesterol and cholesterol levels were measured using a biochemical analyzer. Hcy and blood lipid levels as well as National Institute Health of Stroke Scale (NIHSS) score were determined in each group. Hcy and blood lipid levels were correlated with NIHSS score. Results:Hcy level in the progressive ischemic stroke group was significantly higher than that in the non-progressive ischemic stroke group [(28.39 ± 4.36) μmol/L vs. (20.17 ± 3.24) μmol/L, t = 18.894, P < 0.05]. Low-density lipoprotein cholesterol , triacylglycerol and TC levels in the progressive ischemic stroke group were (3.29 ± 0.45) mmol/L, (2.08 ± 0.34) mmol/L and (4.82 ± 0.79) mmol/L, respectively, which were significantly higher than those in the non-progressive ischemic stroke group [(2.48 ± 0.37) mmol/L, (1.56 ± 0.29) mmol/L and (4.08 ± 0.43) mmol/L, t = 17.644, 14.859, 9.860, P < 0.05]. High-density lipoprotein cholesterol level in the progressive ischemic stroke group was significantly lower than that in the non-progressive ischemic stroke group [(1.03 ± 0.13) mmol/L vs. (1.19 ± 0.14) mmol/L, t =11.158, P < 0.05]. NIHSS score in the progressive ischemic stroke group was significantly higher than that in the non-progressive ischemic stroke group [(21.72 ± 4.35) points vs. (15.52 ± 2.89) points, t = 14.582, P < 0.05]. Hcy, low-density lipoprotein cholesterol, cholesterol and triacylglycerol levels were linearly and positively correlated with NIHSS score ( r = 0.846, 0.724, 0.718, 0.765, all P < 0.05), while igh-density lipoprotein cholesterol level was linearly and negatively correlated with NIHSS score ( r = -0.710, P < 0.05). Conclusion:In patients with progressive ischemic stroke, Hcy level is increased and blood lipid level is obviously abnormal. Hcy and blood lipid levels are greatly correlated with neurological function.

目的:对比分析慢性酒精中毒患者的临床和电生理特点.方法:将2018年1月至2020年12月时段的临床资料调取出来,从中随机抽取50例慢性酒精中毒患者作为观察组,再随机抽取50例在我院进行肌电图检查的健康人员作为对照组,进行对比试验,对比两组人员检查后的电生理特点.结果:(1)正中神经、尺神经、胫后神经、腓总神经、腓肠神经、腓浅神经的传导速度和波幅数值,观察组明显低于对照组,差异具有统计学意义(P<0.05);(2)慢性酒精中毒患者的主要临床症状为肢体麻木、头痛、肢体乏力、头晕、走路不稳、记忆力下降、计算力下降、意识障碍、小便失禁、四肢抽搐等,主要电生理特点为周围性感觉障碍现象、腱反射减低或者消失的现象、双手震颤.结论:肌电图能够敏锐地检测出慢性酒精中毒患者的神经状态,结合临床症状及电生理特点,能够帮助医生判断患者的病情变化,以便更好地进行治疗,具有较高的临床应用价值.

目的 探讨多巴丝肼治疗帕金森病(PD)和血管性帕金森综合征(VP)的疗效及对血浆维生素B12(Vit B12)、叶酸(FA)、同型半胱氨酸(Hcy)、载脂蛋白B100(ApoB100)及脂蛋白-α(LPα)等的影响.方法 回顾性分析55例PD患者(PD组)、50例VP患者(VP组)和50例同期健康体检者(对照组)的临床资料,比较PD组、VP组采用多巴丝肼治疗8周后的临床疗效和治疗前后血清Vit B12、FA、Hcy、ApoB100及LPα水平变化.结果 治疗8周后,PD组和VP组的临床总有效率差异无统计学意义(P＞0.05).治疗前,VP和PD组的VitB12、Hcy、ApoB100、LPα水平均高于对照组(均P＜0.05);治疗8周后,PD组Vit B12、ApoB100水平较治疗前高,Hcy、LPα水平较治疗前低,VP组ApoB100水平较治疗前高,Hcy水平较治疗前低(均P＜0.05).结论 多巴丝肼治疗PD的机制可能与升高VitB12、ApoB100,降低Hcy、LPα有关,治疗VP的机制可能与升高ApoB100,降低Hcy有关.

目的探讨缬沙坦对高血压病患者APN、hs-CRP、TNF-α的调节作用。方法将80例1-2级原发性高血压患者随机分为治疗组和对照组各40例,治疗组予以缬沙坦80mg,1日1次,若4周后血压仍不达标(>140/90mmHg),则缬沙坦1日160mg,对照组患者予以硝苯地平缓释片10mg,1日2次,若4周后血压仍不达标,则硝苯地平缓释片20mg,1日2次,两组均8周为一疗程。结果两组所有患者均在8周内实现血压达标,两组血压达标率及达标时血压情况基本一致(P>0.05)。治疗前,两组APN、hs-CRP和TNF-α含量基本一致(均P>0.05)。治疗一个疗程后,治疗组APN有所升高(P<0.05),而对照组APN变化不明显(P>0.05);两组hs-CRP和TNF-α含量均有所下降(均P<0.05),但治疗组降低比对照组更明显(均P<0.05)。结论缬沙坦对高血压病患者外周血中APN、hs-CRP、TNF-α的含量有一定的调节作用,可能有利于改善高血压患者的预后。

目的:探讨IL-18、NO、ET检测对冠心病(CHD)患者冠脉狭窄程度的临床价值.方法:检测冠状动脉不同狭窄程度CHD患者外周血IL-18、NO、ET的含量.结果:重度狭窄组IL-18、ET含量高于中度狭窄组(P<0.05),NO含量低于中度狭窄组(P<0.05);中度狭窄组IL-18、ET含量高于轻度狭窄组(P<0.05),NO含量低于轻度狭窄组(P<0.05);轻度狭窄组IL-18、ET含量高于正常对照组(P<0.05),NO含量低于正常对照组(P<0.05).结论:临床可通过检测CHD患者血浆中IL-18、NO、ET的含量,作为评价冠脉狭窄程度严重程度的指标.